The CADD522compound also delayed and/or inhibited tumor formation in an aggressive spontaneous model of mammary carcinoma and reduced tumor growth of a RUNX2-expressing patient-derived xenograft (PDX), supporting that CADD522 has therapeutic potential for BC in vitro and in vivo. This evidence concerns the gene RUNX2 and neoplasm.